UBS Healthcare Summit 2018

Singapore, October 19, 2018


Highlights from the summit

The future of healthcare

Key themes like transformative trends and enabling innovations in the healthcare industry will take center stage in this year's UBS Healthcare Summit 2018. By providing an exceptional platform to deepen networks in the industry, the summit brings together forward-thinking leaders, captains of industry and renowned speakers who are at the forefront of the transformative trends in healthcare, life science and technologies.

Thematic topics include:

  • The future of healthcare
  • Singapore's biotech inflexion
  • Living to 150
  • Big data and artificial intelligence
  • Disruptive healthcare business models
  • Investment opportunities in healthcare


Friday, October 19, 2018








Registration and standing buffet lunch

Opening of Discovery Booths


12:30 – 12:40


Welcome remarks

August Hatecke, Head of UBS Wealth, Head of Wealth Management South East Asia, UBS Wealth Management


12:40 – 13:00


Singapore's biotech inflexion

Dr. Benjamin Seet, Executive Director, Biomedical Research Council, A*STAR


13:00- 13:30


The future of healthcare

Daniel Kraft, M.D., Chair for Medicine, Singularity University, Founder & Chair, Exponential Medicine


13:30 – 14:10


Disruptive healthcare business models

Panel speakers:

  • Dr. Carolyn LAM Su Ping, Founder and Chief Scientist,
  • Jon Richards, Chief Financial Officer, Halodoc
  • Yin FAN, Managing Director, Ping An Good Doctor


Dr. Jeremy Lim, Partner, Health & Life Sciences, Asia Pacific, Oliver Wyman


14:10 – 14:30


Living to 150

Dr. Alex Zhavoronkov, Founder and Chief Executive Officer, Insilico Medicine Inc.


14:30 – 14:50


Managing digitalized life

Ying Rui LI, Co-Founder and Chief Scientist, iCarbonX


14:50 – 15:10


Refreshment break


15:10 – 15:55


Discovery Showcase

  • Showcase 1:
    Gavin Tan, Founding Director and Group Chief Executive Officer, CellResearch Corporation
  • Showcase 2:
    Dr. Per Lundin, Co-Founder and Chief Operating Officer, Evox Therapeutics
  • Showcase 3:
    Dr. Patrick Anquetil, Chief Executive Officer, Portal Instruments, Inc.


15:55 - 16:30


From idea to market - Commercial success stories

Panel speakers:

  • Dr. Hardy TS Kagimoto, Chairman and Chief Executive Officer, HEALIOS K.K.
  • Ammar Qadan, Vice-President and Global Head of Market Access, Illumina Inc.


Dr. Stephen Phua, Staff Consultant, Pavilion Capital International Pte Ltd


16:30 – 17:10


Investment opportunities in healthcare – Where would you put your money in?

Panel speakers:

  • Juerg Nagel, Partner, MIV Asset Management
  • Abrar Mir, Managing Partner, Quadria Capital Investment Management Pte Ltd
  • Dr. Christiana Bardon, Founder and Managing Member Burrage Capital, An affiliate fund of MPM


Kelvin Tay, Regional Chief Investment Officer, UBS Global Wealth Management


17:10 – 17:20


Closing remarks

August Hatecke, Head of UBS Wealth, Head of Wealth Management South East Asia, UBS Wealth Management


17:30 – 18:30


Cocktail Reception

Venue: Bob's Bar, Capella Singapore




Event concludes


UBS Host

August Hatecke

Head of UBS Wealth, Head of Wealth Management South East Asia, UBS Wealth Management

August Hatecke was appointed Head of UBS Wealth Management South East Asia in April 2016. August previously served as UBS Head of Ultra High Net Worth and Global Family Office Switzerland based in Zurich where he was responsible for managing the needs of wealthy clients in Switzerland.

August started his career with the Investment Banking arm of SBC O’Connor Warburg Dillon Read (the fore-runner to UBS) in 1994 before moving to Private Banking where he was working on Active Advisory, Portfolio Management, Treasury and Execution. He was with Credit Suisse AG for the period 2001-2010 where he headed teams in Private Banking Switzerland, Investment Services and Products as well as Trading and Sales. Since returning to UBS in 2010, he has been responsible for the Ultra High Net Worth and Global Family Office business for UBS Switzerland AG. August holds a Master Degree in Economics from the University of Zurich.

Master of Ceremony

Nicholas Cheng

Executive Director, Direct Investment Group, UBS Wealth Management

Nicholas Cheng is Executive Director at UBS AG, Singapore and heads the Direct Investments Group for UBS Wealth Management APAC. He has almost 25 years of banking and capital markets experience across trading in Private and Public Market special situations to corporate debt restructuring advisory prior to joining Wealth Management.

Nicholas graduated from the University of Oregon, Eugene with Magna Cum Laude and majored in Finance, Marketing and Economics.

Speakers & Panelists

Dr. Patrick Anquetil

Chief Executive Officer, Portal Instruments, Inc.

As Portal Instrument’s Chief Executive Officer, Dr. Patrick Anquetil brings more than 18 years of experience in building world-class teams and leading high-tech bioengineering companies from the lab to the market place. Prior to founding Portal Instruments, he was Co-Founder of SynapDx Corp., an autism diagnostic company. Dr. Anquetil began his career as a science and nanotechnology equity research analyst at Susquehanna International Group, authoring and marketing industry and equity research reports to hedge funds and portfolio managers.

Dr Patrick He holds a doctorate in bio-instrumentation from MIT, an MBA from Harvard Business School, and a master's degree from the ETH in Zurich and the University of Tokyo. His scientific work has appeared in peer-reviewed publications as well as mainstream media, including MIT Technology Review, Wired Magazine, PBS, and CNBC.

Dr. Christiana Bardon

Founder and Managing Member Burrage Capital, An affiliate fund of MPM

Dr. Christiana Bardon, M.D., is a Managing Director of the UBS Oncology Impact Fund (OIF) managed by MPM. Dr. Bardon is also the Founder and managing member of Burrage Capital, an affiliate fund of MPM which invests in public biotechnology and medical technology. Previously, she was a health care analyst at Fidelity Investments covering biotechnology, life science tools and diagnostics. She started her career as an analyst at MPM. Dr. Bardon focuses on the public equity component of the OIF.

Dr. Bardon earned her MS/BS from MIT, her MD magna cum laude from Harvard Medical School, and her MBA from Harvard Business School. While at Harvard Medical School, Dr Bardon was the recipient of a Howard Hughes fellowship. She also completed a residency in internal medicine at the Brigham and Women’s Hospital at Harvard Medical School. Dr Bardon currently serves on the Board of Fellows at Harvard Medical School.


Managing Director, Ping An Good Doctor

Yin FAN is the Managing Director of Ping An Good Doctor, the biggest China’s online healthcare platform backed by Ping An Insurance (Group). Yin is in charge of the company’s Investment/ Acquisition, Strategy and Capital Market Management, including the recent IPO.

Prior to joining Ping An Good Doctor, Yin was working on the buy side, focusing on healthcare and Telecom, Media and Technology sector ranging from VC investment to cross-border buyout. Before entering into the private equity space, Yin was also the founding partner of two medical device companies in China and the United States.

Dr. Hardy TS Kagimoto

Chairman and Chief Executive Officer, HEALIOS K.K.

Dr. Hardy TS Kagimoto, M.D., is the Chairman and Chief Executive Officer of HEALIOS K.K. After working at Kyushu University hospital, he founded his first biotech company, Aqumen, and launched BBG250 which gained de-facto-standard status in the ophthalmology community, globally. He then founded Healios in 2011 to realize his driving objective, the development of a therapy for age-related macular degeneration.

Healios was listed on the Tokyo Stock Exchange in 2015 and is currently running a P2/3 somatic stem cell product trial for acute brain stroke in Japan. Healios has built a robust pipeline consisting of various iPSC and somatic stem cell therapies addressing several indications. With his experience of taking products from discovery through commercialization, and his vision for the rapid progression of regenerative medicine products to treat disease and enrich quality of life, Dr. Kagimoto is making effort to create a world leading regenerative medicine and cell therapy company.

Daniel Kraft, M.D.

Chair for Medicine, Singularity University, Founder & Chair, Exponential Medicine

Daniel Kraft is a Stanford and Harvard trained physician-scientist, inventor, entrepreneur, and innovator. With over 25 years of experience in clinical practice, biomedical research and healthcare innovation, Kraft has chaired the Medicine for Singularity University since its inception in 2008, and is the Founder and Chair of Exponential Medicine, a program that explores convergent, rapidly developing technologies and their potential in biomedicine and healthcare.

Following undergraduate degrees from Brown University and medical school at Stanford, Daniel was Board Certified in both Internal Medicine & Pediatrics after completing a Harvard residency at the Massachusetts General Hospital & Boston Children's Hospital, and fellowships in hematology, oncology and bone marrow transplantation at Stanford.

He has multiple scientific publications and medical device, immunology and stem cell related patents through faculty positions with Stanford University School of Medicine and as clinical faculty for the pediatric bone marrow transplantation service at University of California San Francisco.

Dr. Carolyn LAM Su Ping

Founder and Chief Scientist,

Dr. Carolyn LAM is Co-Founder of, Professor at Duke-NUS and Director of the Clinical & Translational Research Office at NHCS. She is the Programme Lead of ATTRaCT – an A*STAR Biomedical Research Council-funded research platform, as well as an Associate Editor for Circulation and the European Journal of Heart Failure. In addition, she has a global podcast “Circulation On The Run” and is Resident Doctor on the tv programme “Body and Soul”.

Dr. LAM graduated from National University of Singapore, and pursued her Research Fellowship at the Mayo Clinic. She received further training in clinical and genetic epidemiology at the Framingham Heart Study in Boston, graduated from the Stanford Business School Executive Programme and obtained her PhD at University Medical Centre Groningen.

Ying Rui LI

Co-Founder and Chief Scientist, iCarbonX

Ying Rui LI, is the Co-Founder and Chief Scientist of iCarbonX. In 2006, he joined BGI and became Chief Scientist of BGI in 2010. He led BGI research team to initiate and engage a number of national projects, including Yan Huang Project, 1000 Genomes Project, Yan Huang Whole Genome Methylation, Cancer Genome Project and so on. By far, he has more than 130 papers published in high-impact journal including Nature and Science. His own research interests include algorithms and data structures, computer programming, mathematical statistics, modeling methods, data mining techniques and genomics analysis.

In 2015, Ying Rui left BGI and co-founded iCarbonX, a new data-driven healthcare platform company as chief scientist. He was among the 2014, 2016 & 2017 Thomson-Reuters Highly-cited Researchers and 2015 Forbes 30 under 30 on healthcare sciences.

Dr. Jeremy Lim

Partner, Health & Life Sciences, Asia Pacific, Oliver Wyman

Dr. Jeremy Lim has extensive experience consulting and advising multinational clients on national and regional strategies for market positioning and expansion, including acquisitions and responses to regional healthcare reform. Dr. Lim is also active in academia, holding appointments at several universities. He also writes regularly for both the scientific and popular media, and in 2013 authored Myth or Magic.

Prior to joining Oliver Wyman, Dr. Lim worked in senior executive roles in both public and private sectors, including time spent as a senior official in the Ministry of Health Singapore. Dr. Lim chairs the steering committee of NIHA (NUS Initiative to Improve Health in Asia), an initiative to strengthen health policy research and education in Asia, is a Member of the International Advisory Board, Health Authority Abu Dhabi, and sits on the Advisory Council Behavioural Sciences Institute, Singapore Management University. He also contributes as President of the Fulbright Association (Singapore) and convener for the Johns Hopkins Bloomberg School of Public Health Singapore alumni. A medical doctor by training, Dr. Lim holds a Master’s in public health degree from the Johns Hopkins School of Public Health and a Master’s in medicine (surgery) from the National University of Singapore.

Dr. Per Lundin

Co-Founder and Chief Operating Officer, Evox Therapeutics

Dr. Per Lundin joined Evox in May 2017 as Chief Operating Officer having led the process of raising £10m in seed funding and spinning out the company from University of Oxford and the Karolinska Institutet. Prior to joining Evox, Dr. Lundin managed a European business development team for Thomson Reuters IP & Science, working on the interface between intellectual property analytics and strategy consulting. During his tenure at Thomson Reuters, he co-founded and led the clinical-stage stem cell therapy company IsletOne Therapeutics, developing mesenchymal stromal cells (MSCs) for inflammatory pulmonary diseases.

Dr. Lundin received his PhD in medical science from the Karolinska Institutet in Stockholm, his Master of Science in Biotechnology Engineering from the Royal Institute of Technology, and his Master of Business Administration from Stockholm University School of Business.

Abrar Mir

Managing Partner, Quadria Capital

Abrar Mir is the co-founder and Managing Partner of Quadria Capital, one of the largest healthcare-focused private equity firms in Asia, with over US$1.5 billion in managed capital.

Abrar is actively involved in managing the firm and serves on the fund’s Investment Committee. Abrar has led private equity and capital markets transactions with an aggregate value of over US$40 billion across Asia, the U.S. and Europe. Abrar currently serves on the boards of Medica Synergie, Soho Global Health, FV Hospitals, MWH Healthcare, Lablink, Orilus Investments and Medisia Investment Holdings.

Prior to founding Quadria Capital, Abrar was Global Head of Healthcare at Religare Capital Markets. Before that he was a Managing Director at Bank of America Merrill Lynch in London where he was part of the senior leadership team that led the bank’s healthcare investment banking strategy in Europe and Emerging Markets. Abrar received an MPhil in International Law from the University of Cambridge and is fluent in five languages.

Juerg Nagel

Partner, MIV Asset Management

Juerg Nagel joined MIV Asset Management AG in Zurich, Switzerland, in autumn 2000. MIV Asset Management AG is the investment manager of the MIV Global Medtech Fund. Juerg is a Partner, Member of the Management Board and Head of Portfolio Management & Marketing. From 1989 to 1998, Juerg was an investment advisor for institutional clients in Switzerland at Bank Vontobel AG, Zurich, heading this team from 1998 to 2000. Before that, he worked for UBS Switzerland in several functions. In 1991, Juerg received his diploma as a Swiss-Certified Banker.

Dr. Stephen Phua

Staff Consultant, Pavilion Capital International Pte Ltd

Dr. Stephen Phua spent more than 30 years in the pharmaceutical and healthcare industry. As a medical doctor with a wide range of successful senior positions in several multinational companies, Dr. Phua is retained as a staff consultant of Pavilion Capital, a fully owned subsidiary of Temasek and spend the last 7 years with the private equity fund doing healthcare investment in Asia.

He is also the Chairman of Menarini Biomarkers, a leader in single cell Omics. Throughout his extensive career in the health and life science industry, Dr. Phua has held senior executive appointments spanning across a wide range of the healthcare sectors – biopharmaceuticals, devices, diagnostic and hospital services in Asia Pacific.

Ammar Qadan

Vice-President and Global Head of Market Access, Illumina Inc.

Ammar Qadan is the Vice President and Global Market Access Lead at Illumina; a company whose mission is “to improve human health by unlocking the power of the genome”. In his current job, Ammar is responsible for Health Economic Outcomes Research, Market Access/Pricing strategy, Field Market Access, Payer Policy and Advocacy. Through his career, Ammar has been distinguished as a passionate, patient-focused Biotech leader who worked on multiple disease areas and biotechnology- related strategic programs and major corporate initiatives across functions and geographies.

Before joining Illumina, Ammar was the Vice President and Global Product Team Lead at Halozyme Therapeutics, a Biotech focused on Oncology development in San Diego. He was instrumental in revamping their lead biomarker-driven oncology program strategy, leading to new clinical development programs and a major partnership with Roche/Genentech. Ammar is a Pharmacist by training.

Jon Richards

Chief Financial Officer, Halodoc

Jon Richards joined HaloDoc in 2016 as the Chief Financial Officer. Previously, Jon was the Head of Investment Banking for Valbury Asia Securities in Jakarta for 5 years. Prior to that, he worked at Rohatyn Group in Hong Kong and New York for 2 years.

Between 2006 to 2009, Jon worked as Manager of Development Asia Pacific and MENA for Jumeirah Group in Dubai. He holds a bachelor's degree from London School of Economics and a MBA from Hong Kong University of Science and Technology.

Dr. Benjamin Seet

Executive Director, Biomedical Research Council, A*STAR

Dr. Ben Seet is the Executive Director, Biomedical Research Council at A*STAR, where he oversees research and innovation efforts spanning the pharmaceutical, biotech, med tech, food & nutrition, and consumer care industries. Prior to joining A*STAR, he served a 22-year military career, during which he held appointments of Chief of the SAF Medical Corps, and Chief Medical Officer of the UN Department of Peacekeeping Operations in New York.

Ben has served on various boards and advisory committees, including for the United Nations, Ministry of Health, National Medical Research Council, Health Promotion Board, Agri-food and Veterinary Authority, Lee Kong Chian School of Medicine, and ST Engineering. He holds a Master of Medicine from NUS, Master of Public Health from Johns Hopkins University, and a Fellowship from the Royal College of Surgeons in Edinburgh.

Gavin Tan

Founding Director and Group CEO, CellResearch Corporation

Gavin Tan is the founding director and Group CEO of the CellResearch Corporation Group of Companies. With an active interest in the life sciences sector, Gavin recognized the growth potential of the industry when in 2002, he invested and co-founded CellResearch Corporation. He has been instrumental in charting the strategy and growth of CellResearch Corporation and its subsidiaries. Concurrently, Gavin is a Co-Founder and Partner of Aglaia Family Office.

With over 26 years of experience in Asian financial markets, Gavin began his career as an analyst at Peregrine Securities. He subsequently moved to join the institutional sales desk at CLSA and also spent time in this capacity at Deutsche Morgan Grenfell. For 7 years, Gavin was Head of Institutional Sales at Nomura where he was responsible for directing the institutional equity business in Singapore and Malaysia.

Kelvin Tay

Regional Chief Investment Officer, UBS Global Wealth Management

Kelvin Tay is the Regional Chief Investment officer from UBS Chief Investment Office. Kelvin is a member of the UBS Global Emerging Markets Investment Committee, as well as the Asia Investment Committee where he provides strategic research and inputs to the investment and asset allocation process.

Kelvin joined UBS Wealth Management in April 2006 as a deputy head of P&S Consulting for Southeast Asia, where he helped clients structure investment portfolios based on asset allocation. Prior to joining UBS, Kelvin worked at Deutsche Bank Private Wealth Management (Asia) as the Asian & European Equity Strategist responsible for Asian & European equity selection.

Kelvin received his MBA from Imperial College, University of London in 1999. He also holds a Bachelor of Social Science and Bachelor of Arts from National University of Singapore.

Dr. Alex Zhavoronkov

Founder and Chief Executive Officer, Insilico Medicine Inc.

Dr. Alex Zhavoronkov is the Founder and Chief Executive Officer of Insilico Medicine, a Baltimore-based leader in the next-generation artificial intelligence and blockchain technologies for drug discovery, biomarker development, and aging research. Prior to Insilico, he worked in senior roles at ATI Technologies, NeuroG Neuroinformatics, the Biogerontology Research Foundation and YLabs.AI.

Since 2012, he published over 100 peer-reviewed research papers and two books. He organizes the annual Artificial Intelligence and Blockchain for Healthcare Forum at EMBO/Basel Life in Basel. Dr. Zhavoronkov is an adjunct professor at the Buck Institute for Research on Aging.

Discovery Booths

Advent Access

A medical technology startup focused on end-stage renal disease management. As a spin-off from A*STAR, Advent Access’ mission is to pioneer innovations to significantly reduce dialysis cost and restore quality of life for kidney failure patients.

Its award-winning implant technology, av-Guardian™, aims to improve vascular access reliability, enable less-painful self-cannulation, and in the long run, potentially reduce vascular access surgeries or hospitalizations. Its dialysis-machine agnostic platform seeks to transform hemodialysis to be performed independently, safely and more affordably, by enabling labor-light dialysis to be delivered in novel or alternative care environments.


Traditional Chinese medicine is wisdom from our ancestors that has been passed down for thousands of years. In the era of Western medicine that values data, traditional Chinese medicine is often viewed as purely experience-oriented.

Aetoscan combines Eastern traditional medicine and Western science to create its Energy Health Check-Up System. It is an energy detection system that measures 24 acupuncture points. The "Meridian Machine" developed based on the Huangdi Neijing could be significantly upgraded through modern technologies.

Fourier Intelligence

Fourier Intelligence believes that technology can push the human to go beyond of their physical limits. The company is a believer of Artificial Intelligence and Human Machine Collaboration.

Since 2015, it has been producing the exoskeleton and rehabilitation robotic products in Shanghai and Singapore. The aim is to assist and cover the whole rehabilitation process, transfer the human capabilities and finally surpass limits.

MIV Asset Management AG

MIV Asset Management AG is an asset manager of collective investment schemes authorised by the Swiss Financial Market Supervisory Authority (FINMA).

The long-standing team of this Zurich-based investment boutique consists of five experienced financial and medical device analysts/portfolio managers and an assistant. MIV Asset Management AG is the investment manager of the MIV Global Medtech Fund.

The MIV Global Medtech Fund invests globally in listed medical device companies. Owing to demographic trends, the desire for quality of life and mobility, the expansion of healthcare systems in emerging markets as well as the development and launch of innovative products, the medical device industry is a long-term growth market.


Prenetics is a leading consumer genetic testing company with a global presence. Headquartered in Hong Kong, it has offices in 8 countries across 3 continents. Prenetics believes that “Prevention is Better Than Cure” and aims to help people to take control of their health.

By empowering individuals with powerful health information based on their genes, Prenetics enables individuals to better understand their genetic predispositions in areas such as diet, fitness, cancer, disease and medication. Equipped with such knowledge, individuals can then learn how to actively manage their health through lifestyle adjustments and reduce associated health risks in the long-term.


Learn how we can help you meet your wealth management needs today.